<?xml version="1.0" encoding="UTF-8"?>
<p id="para530">Various combinations of gemcitabine with platinum and steroid in relapsed or refractory peripheral T-cell lymphoma have also been reported in the scientific literature with encouraging results (objective response 36%–100%) and acceptable toxicity.
 <xref rid="bib12" ref-type="bibr">12</xref>, 
 <xref rid="bib13" ref-type="bibr">13</xref>, 
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib17" ref-type="bibr">17</xref>, 
 <xref rid="bib18" ref-type="bibr">18</xref>, 
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib28" ref-type="bibr">28</xref> Specifically, the GEM-P regimen has been assessed in three retrospective studies including patients with peripheral T-cell lymphoma, predominantly with relapsed or refractory disease, with reported objective responses of 69%–100% (complete response 19%–50%) and some durable remisisons.
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref> Furthermore, some novel regimens incorporating gemcitabine have been assessed in treatment-naive patients in the peripheral T-cell lymphoma setting,
 <xref rid="bib4" ref-type="bibr">4</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref>, 
 <xref rid="bib29" ref-type="bibr">29</xref>, 
 <xref rid="bib30" ref-type="bibr">30</xref> including one randomised trial,
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> and all have shown encouraging results for gemcitabine in this indication excepting one.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> In one trial, patients were assigned either to CHOP (n=51) or a combination of gemcitabine 800 mg/m
 <sup>2</sup> on days 1 and 8, cisplatin 25 mg/m
 <sup>2</sup> intravenously on days 1–3, prednisolone 60 mg/m
 <sup>2</sup> orally on days 1–5, and thalidomide 200 mg orally once per day continuously (n=52); this regimen was associated with a significant improvement in the proportion of patients achieving a response, 2-year progression-free survival, and 2-year overall survival.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref>
</p>
